Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system, caused by the polyomavirus JC and occurring almost exclusively in the context of severe immune depression. AIDS represents the most common predisposing condition for PML development. Antiretroviral treatment has reduced PML incidence in HIV-infected subjects, but the disease remains a severe and life-threatening complication of AIDS, considering thus far the lack of an effective anti-JC virus (JCV) direct-acting antiviral drug. In the last decade, the use of monoclonal antibodies for treating immune-based diseases evidenced new predisposing conditions for PML development, promoting a renewed interest in PML pathogenesis. In this article, we review the current knowledge on JCV epidemiology and AIDS-associated PML incidence, JCV viral cycle, pathogenesis, and the interplay with HIV infection. We give an updated overview of diagnostic and prognostic tools available for PML diagnosis and describe past and current therapeutic approaches, including new strategies for PML cure.

HIV-associated progressive multifocal leukoencephalopathy. Current perspectives / Iannetta, M.; Zingaropoli, M. A.; D'Abramo, A.; Oliva, A.; Mastroianni, C. M.; Vullo, V.; Ciardi, M. R.. - In: NEUROBEHAVIORAL HIV MEDICINE. - ISSN 1179-1497. - 7:(2016), pp. 43-52. [10.2147/NBHIV.S107941]

HIV-associated progressive multifocal leukoencephalopathy. Current perspectives

Iannetta M.;Zingaropoli M. A.;D'Abramo A.;Oliva A.;Mastroianni C. M.;Vullo V.;Ciardi M. R.
2016

Abstract

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system, caused by the polyomavirus JC and occurring almost exclusively in the context of severe immune depression. AIDS represents the most common predisposing condition for PML development. Antiretroviral treatment has reduced PML incidence in HIV-infected subjects, but the disease remains a severe and life-threatening complication of AIDS, considering thus far the lack of an effective anti-JC virus (JCV) direct-acting antiviral drug. In the last decade, the use of monoclonal antibodies for treating immune-based diseases evidenced new predisposing conditions for PML development, promoting a renewed interest in PML pathogenesis. In this article, we review the current knowledge on JCV epidemiology and AIDS-associated PML incidence, JCV viral cycle, pathogenesis, and the interplay with HIV infection. We give an updated overview of diagnostic and prognostic tools available for PML diagnosis and describe past and current therapeutic approaches, including new strategies for PML cure.
2016
diagnosis; iris; jcv; neuroaids; pml; therapy
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
HIV-associated progressive multifocal leukoencephalopathy. Current perspectives / Iannetta, M.; Zingaropoli, M. A.; D'Abramo, A.; Oliva, A.; Mastroianni, C. M.; Vullo, V.; Ciardi, M. R.. - In: NEUROBEHAVIORAL HIV MEDICINE. - ISSN 1179-1497. - 7:(2016), pp. 43-52. [10.2147/NBHIV.S107941]
File allegati a questo prodotto
File Dimensione Formato  
Iannetta_HIV-associated_2016.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 500.17 kB
Formato Adobe PDF
500.17 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1306122
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact